2nd InSite User Group Meeting: from plans and ambitions to results!19 Feb 2018
On February 8th, we welcomed more than 60 representatives from hospitals, pharmaceutical companies and CROs from all over Europe for the 2nd InSite User Meeting. The conference brought together InSite's partners and those interested in joining the network to share their insights and exchange best practices on the use of real-world data.
We would like to thank our speakers and all those who attended for making this day a success. In one year's time we went from presenting ambitions and plans to impressive results making InSite's power tangible.
The meeting highlights
IRST (Italy) and Clinica Universidad de Navarra (Spain) presented the initial results of their pilot recruitment studies demonstrating the ability to find more eligible patients in minutes instead of weeks!
Our pharma partners shared their perspective on InSite’s benefits. The platform enables bringing new therapies to patient faster at a reduced cost, for example by designing protocols more efficiently and preventing costly amendments, thanks to the ability to test them on real world data.
Turku University Hospital (Finland) has joined the pilot program for academics. We are actively recruiting additional universities that want to participate in this program, so be sure to get in touch if you are interested!
Other presentations highlighted the importance of good data recording practices. Whether for use in trials, or to optimize patient treatment plans, high-quality data is imperative to prevent certain biases and draw the right conclusions. Joibn InSite and leverage Custodix’ expertise to optimize your data quality, mapping it to international (European) standards, free of charge.
An IT workshop allowed some attendees to dive deeper into the technical aspects of the platform. In parallel, a Q&A session stimulated the discussion between all partners on how they would like to see the platform evolve. An important driver of innovation is the EHR2EDC project, expanding InSite's applications to trial execution, in which a sneak peek was given.
We look forward to welcoming you to the next edition!